Evidence map›Paper›PMID 34181232›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene.

Y L Wang, R H Liang, C Y Wang, R P Zhang, S Y Wu, X Han, G L Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Actin-Like Protein 6A as an Oncogene and Therapeutic Target in Cancer.International journal of medical sciences · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Y L WangDepartment of Medical Oncology, Baotou Cancer Hospital, Baotou, 014030, Inner Mongolia, China.
R H LiangDepartment of Medical Oncology, Baotou Cancer Hospital, Baotou, 014030, Inner Mongolia, China.
C Y WangDepartment of Medical Oncology, Baotou Cancer Hospital, Baotou, 014030, Inner Mongolia, China.
R P ZhangDepartment of Medical Oncology, Baotou Cancer Hospital, Baotou, 014030, Inner Mongolia, China.
S Y WuDepartment of Medical Oncology, Baotou Cancer Hospital, Baotou, 014030, Inner Mongolia, China.
X HanDepartment of Breast Surgery, Baotou Cancer Hospital, No. 18 Tuanjie Street, Qingshan District, Baotou, 014030, Inner Mongolia, China.
G L ZhangDepartment of Breast Surgery, Baotou Cancer Hospital, No. 18 Tuanjie Street, Qingshan District, Baotou, 014030, Inner Mongolia, China. njmucc2@163.com.ORCID http://orcid.org/0000-0003-1510-0330
Baotou Medical College · CNInner Mongolia University of Science and Technology · CN

Funding

Jiangsu Health Commission Y20180808Jiangsu Institute of Cancer Research Fund ZM201814Jiangsu Youth Fund BK20181091
6 · The paper itself

Abstract

purposeTo investigate the effect of microRNA-543 (miR-543) on the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of triple-negative breast cancer (TNBC) cells, and the associated mechanism.

methodsHuman breast cancer cells (MDA-MB-231, HCC1937, and MCF-7, ZR-75-1) and normal human breast epithelial cell line (MCF10A) were transfected with miR-543 mimics or inhibitor using lipofectamine 2000. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting were used to determine the mRNA and protein expression levels of miR-543, actin-like protein 6A (ACTL6A), vimentin, Snail, and E-cadherin in breast cancer cells/tissue. Cell counting kit-8 (CCK-8), wound-healing, and Transwell assays were used to measure the effect of miR-543 on TNBC cell proliferation, invasion, and migration. Overall survival was determined using data from Gene Expression Omnibus (GEO) and Cancer Genome Atlas (TCGA) databases. Bioinformatics analysis and luciferase reporter gene assay were used to determine the regulatory effect of miR-543 on ACTL6A.

resultsThe level of expression of miR-543 was significantly lower in breast cancer cells/tissue than in normal human breast epithelial cell/tissue (p < 0.05). MicroRNA-543 expression level was significantly reduced in TNBC cells/tissue, relative to the other breast cancer cells/normal breast tissue (p < 0.05). MicroRNA-543 significantly suppressed tumor growth and the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of TNBC cells, in mouse xenograft model (p < 0.05).

conclusionsmiR-543 influences the biological behavior of TNBC cells by directly targeting ACTL6A gene. miR-543 could serve as a novel diagnostic and therapeutic target for TNBC.

Indexed as

Cell MovementCell ProliferationDown-RegulationEpithelial-Mesenchymal TransitionActinsAnimalsChromosomal Proteins, Non-HistoneDNA-Binding ProteinsHumansMiceMicroRNAsNeoplasm InvasivenessTriple Negative Breast NeoplasmsTumor Cells, CulturedActinsACTL6A protein, humanChromosomal Proteins, Non-HistoneDNA-Binding ProteinsMicroRNAsMIRN543 microRNA, humanActin-like protein 6AEpithelial–mesenchymal transitionMetastasisMicroRNA-543Triple-negative breast cancer

Identifiers

PMID34181232
OpenAlexW3173252869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.